ERBB2 and breast cancer: The current data is in line with previous in vitro results as regards steroid receptor-positive breast cancer, since there was highly significant co-expression of PRDX III and Nrf2 in ER+/PR+/HER2- cases, which may reflect Nrf2-mediated PRDX induction after estrogen-induced oxidative stress.